HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ellen K Ritchie Selected Research

SAR103168

2/2015Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ellen K Ritchie Research Topics

Disease

16Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2022 - 01/2007
7Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2021 - 08/2007
6Leukemia
10/2020 - 11/2006
5Primary Myelofibrosis (Myelosclerosis)
01/2022 - 08/2013
5BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/2021 - 01/2017
4Neoplasms (Cancer)
01/2022 - 01/2020
3Fatigue
01/2021 - 11/2008
3Philadelphia Chromosome
01/2021 - 06/2017
2Residual Neoplasm
01/2021 - 06/2017
2Diarrhea
01/2021 - 11/2008
2Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2021 - 06/2017
2Acute Promyelocytic Leukemia
11/2014 - 11/2008
1Cognitive Dysfunction
01/2022
1Carcinogenesis
01/2021
1Heart Failure
01/2021
1Hyperbilirubinemia
01/2021
1Hypertension (High Blood Pressure)
01/2021
1Polycythemia Vera
01/2021
1Thrombosis (Thrombus)
11/2015
1Hypoalbuminemia
10/2015
1Sepsis (Septicemia)
09/2015
1Febrile Neutropenia
09/2015
1Neutropenia
09/2015
1Stomatitis
09/2015
1Pneumonia (Pneumonitis)
09/2015
1Nausea
11/2008
1Exanthema (Rash)
11/2008
1Edema (Dropsy)
11/2008
1Lymphoma (Lymphomas)
08/2007
1Non-Hodgkin Lymphoma (Lymphosarcoma)
08/2007

Drug/Important Bio-Agent (IBA)

7Cytarabine (Cytosar-U)FDA LinkGeneric
01/2020 - 11/2008
6Tyrosine Kinase InhibitorsIBA
01/2021 - 01/2017
3CPX-351IBA
01/2020 - 03/2011
3Daunorubicin (Cerubidine)FDA LinkGeneric
01/2020 - 03/2011
3DecitabineFDA Link
01/2018 - 08/2011
3Arsenic Trioxide (Trisenox)FDA Link
11/2014 - 11/2008
2blinatumomabIBA
01/2021 - 06/2017
2Pharmaceutical PreparationsIBA
01/2021 - 10/2018
2vosaroxinIBA
11/2018 - 09/2015
2Phosphotransferases (Kinase)IBA
02/2015 - 01/2015
1tirbanibulinIBA
01/2022
1Hemoglobins (Hemoglobin)IBA
01/2022
1ruxolitinibIBA
01/2022
1navitoclaxIBA
01/2022
1pegaspargase (Oncaspar)FDA Link
01/2021
1Asparaginase (Elspar)FDA Link
01/2021
1BilirubinIBA
01/2021
1tosedostatIBA
01/2021
1gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA
01/2021
1Hydroxyurea (Hydrea)FDA LinkGeneric
01/2021
1Proteins (Proteins, Gene)FDA Link
01/2021
1Interferon-alpha (Interferon Alfa)IBA
01/2021
1RO6870810IBA
01/2021
1pemigatinibIBA
01/2020
1Liposomes (Liposome)IBA
10/2018
1guadecitabineIBA
01/2018
1plerixaforFDA Link
01/2018
1InterferonsIBA
07/2017
1CI 22IBA
06/2017
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
11/2015
1Biomarkers (Surrogate Marker)IBA
10/2015
1SAR103168IBA
02/2015
1lestaurtinibIBA
01/2015
1PanobinostatIBA
08/2013
1tipifarnib (R115777)IBA
01/2012
1Etoposide (VP 16)FDA LinkGeneric
01/2012
1Azacitidine (5 Azacytidine)FDA Link
01/2012
1Biological ProductsIBA
08/2011
1Transaminases (Aminotransferases)IBA
11/2008
1Etodolac (Lodine)FDA LinkGeneric
08/2007
1troxacitabineIBA
01/2007
1insulin receptor-related receptor (IRR)IBA
11/2006

Therapy/Procedure

12Therapeutics
01/2022 - 08/2007
5Drug Therapy (Chemotherapy)
01/2021 - 08/2007
1Activities of Daily Living (ADL)
01/2022
1Cell Transplantation
01/2022
1Cell- and Tissue-Based Therapy (Cell Therapy)
10/2020
1Hematopoietic Stem Cell Transplantation
06/2017
1Induction Chemotherapy
08/2011
1Radioimmunotherapy
08/2007
1Radiotherapy
08/2007